Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn's Disease and Ulcerative Colitis.
- DOI
- 10.14740/gr1664
- Published
- 2023 Dec
- Container
- Gastroenterology research
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.14740/gr1664,
title = {Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn's Disease and Ulcerative Colitis.},
author = {Merza N and Nawras Y and Saab O and Dahiya DS and Ahmed Z and Ranabothu M and Boujemaa S and Hassan M and Kobeissy A and Lilley K},
year = {2023},
journal = {Gastroenterology research},
doi = {10.14740/gr1664},
url = {https://doi.org/10.14740/gr1664}
}RIS
TY - JOUR TI - Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn's Disease and Ulcerative Colitis. AU - Merza N AU - Nawras Y AU - Saab O AU - Dahiya DS AU - Ahmed Z AU - Ranabothu M AU - Boujemaa S AU - Hassan M AU - Kobeissy A AU - Lilley K PY - 2023 JO - Gastroenterology research DO - 10.14740/gr1664 UR - https://doi.org/10.14740/gr1664 ER -
APA
N, M., Y, N., O, S., DS, D., Z, A., M, R., S, B., M, H., A, K., & K, L. (2023). Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn's Disease and Ulcerative Colitis.. Gastroenterology research. https://doi.org/10.14740/gr1664
Source records
- pubmed · retrieved 2026-09-26T16:41:58.806Z